Nootropic Peptides: What the Research Actually Says About Selank, Semax, and Dihexa (2025 Evidence Review)

Nootropic peptides occupy an uncomfortable middle ground in the research literature. The advocacy side cites rodent studies as if they were phase III trials. The dismissal side waves off the entire category without engaging with compounds that actually have clinical records. Neither approach is useful for anyone trying to understand what the evidence actually says.

This guide covers three meaningfully different compounds - Semax, Selank, and Dihexa - plus Cerebrolysin as a reference point for what a more developed clinical record looks like in this category. They're not interchangeable. They have different mechanisms, different evidence tiers, different legal statuses, and radically different risk profiles. Treating them as a homogeneous 'nootropic peptide stack' is one of the most common mistakes in community discussion of this area.

What follows is an attempt to apply a consistent evidence-tier framework across all four. The goal isn't to endorse or dismiss any compound, but to establish exactly where each one sits on the research continuum - so readers can calibrate their own assessment of the gaps between rodent data, Soviet-era institutional trials, and replicated Western clinical evidence. All compounds covered are sold as research chemicals in Western jurisdictions and are not approved for human consumption outside specific prescription contexts. This content is for educational purposes only.

Why Cognitive Peptides Deserve a More Rigorous Evidence Framework

The nootropic peptide space has a persistent evidence-quality problem. Community forums aggregate anecdotal reports and present them alongside rodent data as if both carry equal weight. Vendor copy routinely extrapolates from animal models to human outcomes without flagging the gap. Meanwhile, mainstream science communication often dismisses the entire category without distinguishing between compounds with no human data at all (Dihexa) and compounds with decades of institutional clinical use (Cerebrolysin).

The result: readers are often poorly equipped to assess what they're actually looking at. A study in 12 rats using a dose that doesn't extrapolate to human pharmacology is categorically different from a randomized controlled trial in stroke patients. Both exist in this space. Treating them as equivalent is an error.

This guide applies a consistent evidence-tier framework across four compounds. The tiers are: T1 - Replicated human RCT data with independent Western peer review; T2 - Institutional clinical trial data, not fully independently replicated; T3 - Animal model data with biological plausibility, no human trials; T4 - Theoretical mechanism, minimal published data. None of the three featured peptides reach T1. Understanding where each one sits, and why, is the point of this review.

---

What Are Nootropic Peptides? Chemical Classes and Mechanisms of CNS Action

Peptides are short chains of amino acids - typically 2 to 50 residues - that act as signaling molecules in biological systems. 'Nootropic peptides' is an informal category describing peptides that research suggests may influence cognitive function, neuroprotection, neuroplasticity, or mood regulation through central nervous system pathways.

The mechanisms vary substantially by compound:

• Neurotrophic factor modulation - influencing BDNF, NGF, or HGF/MET signaling (Semax, Dihexa)
• GABAergic and enkephalinergic activity - modulating inhibitory tone and endogenous opioid pathways (Selank)
• Neuropeptide-derived fragments - short sequences derived from larger neuropeptides like ACTH or tuftsin (Semax is an ACTH(4-10) analogue; Selank is a tuftsin analogue)
• Mixed neurotrophic/neuroprotective profiles - as seen in hydrolysate preparations like Cerebrolysin

CNS delivery is a critical variable. The blood-brain barrier excludes most peripherally administered peptides unless they use active transport mechanisms or are delivered via routes that partially bypass the barrier - particularly intranasal delivery via the olfactory epithelium. That's why intranasal administration features so prominently in Semax and Selank research protocols.

---

Evidence Tier Framework: How to Read the Research in This Category

Before reviewing individual compounds, it's worth being explicit about what different evidence types can and cannot support:

Animal model data establishes biological plausibility and provides initial safety signals. It doesn't establish human efficacy or safe dosing. Rodent-to-human dose extrapolation is non-trivial and frequently misapplied in community discussion. A compound that produces dramatic cognitive effects in mice at a given dose-per-kilogram doesn't necessarily produce any effect in humans at an allometrically scaled dose.

Institutional clinical data from non-Western regulatory systems - particularly Soviet and post-Soviet Russian trials - occupies a complicated tier. These trials exist, some are peer-reviewed in Russian-language journals, and some compounds (Semax, Selank, Cerebrolysin) achieved formal registration through these processes. However, the regulatory standards applied by Roszdravnadzor (Russia's equivalent of the FDA) are not equivalent to FDA or EMA standards. Independent replication by Western institutions is sparse.

Anecdotal user reports from communities like Longecity, Reddit, and biohacker forums have some value as signal - particularly for identifying side-effect patterns that didn't appear in small trials - but carry no statistical weight and are subject to substantial selection and reporting bias.

Cochrane-level systematic review represents the highest evidence tier in this category. Only Cerebrolysin has attracted this level of analysis, and the findings are instructive.

---

Semax: BDNF Upregulation, Registered Pharmaceutical Status, and the Western Replication Gap

What It Is

Semax is a synthetic heptapeptide - Met-Glu-His-Phe-Pro-Gly-Pro - derived from the ACTH(4-7) fragment with a Pro-Gly-Pro extension. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and registered as a pharmaceutical in Russia in 1996 for use in conditions including stroke, transient ischemic attack, and cognitive impairment. It's sold as a research chemical in Western markets.

Evidence Tier: T2 - Institutional clinical trial data exists; Western replication is limited.

Mechanism of Action

Research suggests Semax increases BDNF (brain-derived neurotrophic factor) expression in the hippocampus and frontal cortex. BDNF is a key mediator of synaptic plasticity, neuronal survival, and learning and memory consolidation. Semax also shows activity at dopaminergic and serotonergic systems in animal models, and preliminary studies report modulation of gene expression involved in vascular and immune response in the CNS.

Intranasal delivery is the primary research administration route. The olfactory epithelium provides a partial bypass of the blood-brain barrier, and animal models report measurable CNS penetration following intranasal dosing.

Evidence Summary

Human trials (T2): Russian clinical trials support Semax registration for stroke recovery and cognitive impairment. Published data from Russian institutions report benefits in attention, memory, and neurological recovery in patient populations. A 2011 study published in *Eksperimental'naya i Klinicheskaya Farmakologiya* reported effects on BDNF expression in healthy volunteers. Sample sizes in available published trials are generally small (under 100 subjects in most reported studies), and independent replication by Western institutions is minimal.

Animal studies: Rodent models consistently show BDNF upregulation, neuroprotective effects in ischemia models, and anxiolytic-adjacent behavioral changes. These findings are more robust than most research peptides, though the usual extrapolation caveats apply.

Anecdotal reports: Self-report forums describe acute effects on focus, verbal fluency, and mood within 30-60 minutes of intranasal dosing. These reports are consistent with the proposed mechanism but carry no controlled-trial weight.

Dosing in Research Contexts

Russian clinical protocols report intranasal dosing in the range of 300-900 mcg per day, divided across multiple administrations, in acute treatment settings. Animal model studies use a wide range of doses. The plasma half-life is approximately 5-10 minutes, which research suggests limits sustained systemic exposure - though it may not limit CNS effects given direct olfactory delivery.

> Disclaimer: Dosing ranges cited here are drawn from published research contexts only. They are not a recommendation for human use. Semax is not approved for human consumption in Western jurisdictions.

Reported Side Effects and Contraindications

Russian clinical literature describes Semax as well-tolerated in trial populations, with nasal irritation as the most commonly reported adverse effect. No significant withdrawal or dependency signals have been reported in short-course protocols. Given the short half-life and non-systemic delivery, systemic side-effect burden appears low in trial data - though the absence of large-scale Western safety surveillance is a meaningful limitation.

---

Research Peptide Semax - Verdict

Best for: Researchers focused on neurotrophin modulation and neuroprotection mechanisms, or those evaluating cognitive peptides with at least some institutional clinical record.

Pros: Genuine registered pharmaceutical status with published trial data - that's an unusual depth of evidence for a research peptide. BDNF upregulation mechanism is well-characterized and biologically plausible. Intranasal delivery is non-invasive and reported to offer rapid CNS access via the olfactory pathway. Relatively mild reported side-effect profile in both clinical and anecdotal contexts.

Cons: Human trial evidence is heavily concentrated in Russian-language literature with limited independent Western replication. The very short plasma half-life (roughly 5-10 minutes) requires careful timing and storage protocols; pre-mixed intranasal solutions degrade rapidly. Research-chemical status in Western jurisdictions means no quality control enforcement and significant batch-to-batch variability risk.

Score: 72/100 (Mid-range)

---

Selank: GABAergic and Enkephalinergic Pathways, Anxiolytic Signals, and the Limits of Soviet-Era Data

What It Is

Selank is a synthetic heptapeptide analogue of the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences - the same institution behind Semax - it was registered in Russia as an anxiolytic drug in 2009. Like Semax, it's sold as a research chemical in Western markets.

Evidence Tier: T2 - Institutional clinical data exists for anxiolytic applications; the mechanism is more complex and less fully characterized than Semax.

Mechanism of Action

Selank's reported mechanisms are more heterogeneous than Semax. Research suggests it influences GABAergic tone (without binding directly to GABA-A receptors the way benzodiazepines do), modulates enkephalin degradation - potentially increasing endogenous opioid peptide availability - and has been reported to upregulate BDNF expression in animal models. It also shows immunomodulatory activity, consistent with its tuftsin-derived structure.

The overlapping pathways are both a feature and a complication. They may explain a broader-than-average effect profile, but they also make mechanistic safety extrapolation more difficult. When a compound affects multiple systems simultaneously, predicting interaction effects and long-term consequences requires more data than is currently available.

Evidence Summary

Human trials (T2): Russian institutional trials support its registration as an anxiolytic. Published studies report reductions in anxiety measures in patients with generalized anxiety disorder, with effect sizes described as comparable to conventional anxiolytics but without sedation or dependence signals. One commonly cited study involved approximately 60 patients in a randomized comparison design. Independent replication outside Russian institutions is essentially absent.

Animal studies: Rodent models show consistent anxiolytic effects, memory-enhancing properties in some paradigms, and BDNF modulation. The immunomodulatory effects are well-documented in animal models.

Anecdotal reports: User reports describe a calm-without-sedation effect, mild cognitive improvement in anxious individuals (consistent with anxiety reduction itself improving performance), and generally low side-effect burden. Some users report nothing notable at commonly discussed doses.

Dosing in Research Contexts

Russian clinical protocols report intranasal dosing in the range of 250-900 mcg per day in anxiolytic applications. The plasma half-life is approximately 1-2 hours - longer than Semax, but still requiring multiple daily doses to maintain consistent research-context exposure.

> Disclaimer: Dosing ranges cited here are from published research contexts only. They are not a recommendation for human use. Selank is not approved for human consumption in Western jurisdictions.

Reported Side Effects and Contraindications

Russian trial data reports no significant adverse effects, no withdrawal syndrome, and no dependency in short-course protocols - a profile that compares favorably to benzodiazepines if the data are taken at face value. The primary caveat is the limited scope of available safety surveillance. The immunomodulatory activity raises theoretical questions about use in autoimmune conditions or alongside immunosuppressive therapy, though no clinical evidence directly addresses this.

---

Research Peptide Selank - Verdict

Best for: Researchers focused on anxiolytic mechanisms without classical GABAergic pharmacology, or those comparing enkephalinergic and GABAergic pathways in anxiety models.

Pros: Formal regulatory approval in Russia provides at least some institutional clinical framework. Intranasal delivery is non-invasive. Side-effect profile in Russian trials is described as favorable, with no dependency signals in short cycles. Relatively affordable per-cycle cost.

Cons: Virtually all controlled evidence comes from Russian institutions with no independent Western replication. Short half-life requires multiple daily administrations. The mechanism involves several overlapping pathways that remain incompletely characterized, which complicates safety extrapolation.

Score: 62/100 (Mid-range)

---

Dihexa: HGF/MET Potentiation, Extraordinary Rodent Potency, and Zero Human Trial Data

What It Is

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, also called PNB-0408) is a small peptide derived from angiotensin IV, developed by researchers at Washington State University. It's not registered as a pharmaceutical anywhere and has not entered human clinical trials as of the time of writing.

Evidence Tier: T3 - Animal model data with biological plausibility. No human trials.

This is a materially different evidence position from Semax or Selank, and it's worth being direct about what that means: there is no human safety data. None. The compound's effects in humans - positive or negative - are unknown.

Mechanism of Action

Research suggests Dihexa acts as a potent agonist at HGF/MET (hepatocyte growth factor / MET proto-oncogene receptor) signaling pathways. HGF/MET activity is implicated in synaptogenesis - the formation of new synaptic connections - and neuronal survival. Washington State University researchers published rodent data suggesting Dihexa is orders of magnitude more potent than BDNF at driving synaptogenesis in hippocampal tissue. The published animal data is striking by any measure in this category.

Evidence Summary

Human trials: None. This isn't a gap in the available literature - it's a categorical absence.

Animal studies (T3): Published research from Washington State University in rodent models reports potent pro-cognitive effects in spatial memory tasks, with claimed potency seven orders of magnitude greater than BDNF in certain in vitro assays. These findings are genuinely notable and constitute a legitimate scientific starting point. They don't constitute evidence of human efficacy or safety.

Anecdotal reports: Reports exist in biohacker communities describing cognitive improvement. The absence of any controlled human data means these reports can't be interpreted meaningfully. They're not even useful for safety signal detection given the small, self-selected reporting population.

The Oncogenic Concern

MET receptor agonism isn't a neutral pharmacological action. The MET pathway is also implicated in oncogenesis - MET amplification is found in several cancer types, and MET inhibitors (not agonists) are being developed as cancer therapeutics. This doesn't mean Dihexa causes cancer. It means there's a theoretical mechanism by which chronic agonism of the MET pathway could have oncogenic implications, and there's no human safety data to evaluate that concern. The concern is unresolved, not dismissed.

Dosing in Research Contexts

Animal model studies use doses in the microgram-per-kilogram range. Human dose extrapolation from these figures isn't straightforward and shouldn't be attempted without human pharmacokinetic data.

> Disclaimer: No human dosing data exists for Dihexa. Any dosing information circulating in community contexts is extrapolation from animal models, not clinical evidence. This is not a recommendation for human use.

Reported Side Effects and Contraindications

No human safety data exists. The theoretical oncogenic concern via MET agonism represents the most significant unresolved safety signal. Animal model data doesn't adequately characterize long-term safety.

---

Research Peptide Dihexa - Verdict

Best for: Pre-clinical research contexts only. The compound represents a scientifically interesting HGF/MET agonist with legitimate academic origins, but the complete absence of human trial data places it in a categorically higher-risk position than Semax or Selank.

Pros: Proposed oral bioavailability reduces injection burden. HGF/MET potentiation mechanism is biologically coherent and grounded in credentialed academic research. Rodent data from Washington State University provides a legitimate scientific starting point. Small required doses per animal literature.

Cons: Zero published human clinical trial data. MET receptor agonism raises unresolved theoretical oncogenic concerns with chronic exposure. Supply chain is entirely unregulated, with no quality assurance infrastructure comparable even to the weak protections that exist for more established research peptides.

Score: 38/100 (Premium pricing relative to evidence base)

---

Cerebrolysin: The Largest Clinical Trial Record in Nootropic Peptides - and What Cochrane Found

Cerebrolysin is included here as a reference point rather than a featured compound. It's a hydrolysate of porcine brain protein containing neurotrophic peptide fragments, and it has the most extensive clinical trial record of any compound in this category - including multiple randomized controlled trials in Alzheimer's disease and stroke rehabilitation.

The 2020 Cochrane review of Cerebrolysin for Alzheimer's disease reviewed 6 trials with a combined 788 participants. The review found some evidence of benefit on global clinical impression scales but described the overall evidence as low-to-moderate quality with methodological limitations, and concluded that benefit remained uncertain when applying Cochrane-standard analysis.

This is instructive for the category as a whole. The compound with the best-documented clinical record in nootropic peptides - more trials, larger sample sizes, more independent replication than anything else in this space - still doesn't meet the threshold for confident efficacy conclusions at Cochrane review standards. Semax and Selank are operating with substantially less evidence than Cerebrolysin. Dihexa is operating with none.

---

Delivery Routes Compared: Intranasal vs. Injectable vs. Oral Bioavailability

Intranasal (Semax, Selank)

Intranasal delivery is the primary research route for both Semax and Selank. The rationale is direct access to the olfactory epithelium, which provides a partial pathway to the CNS that bypasses the blood-brain barrier. Animal model studies support meaningful CNS penetration via this route for both compounds. In practical research terms, it's also non-invasive relative to injection - though solution stability is a real concern. Both peptides in aqueous solution are susceptible to degradation at room temperature.

Injectable (subcutaneous or intramuscular)

Some research protocols use subcutaneous administration for both Semax and Selank. Systemic bioavailability via injection is expected to be higher than intranasal, but CNS penetration still requires active transport mechanisms given the blood-brain barrier. The short half-lives of both compounds mean injectable protocols also require frequent dosing.

Oral Bioavailability

Most peptides are rapidly degraded by gastrointestinal proteases and have negligible oral bioavailability when administered as standard peptide sequences. Dihexa is a notable exception in research discussion - its modified structure is proposed to confer resistance to gastrointestinal degradation, and some animal model data has used oral administration. If this oral bioavailability profile holds in humans - which hasn't been tested - it would be a practical advantage. The theoretical benefit doesn't substitute for human pharmacokinetic data.

---

Side Effect and Safety Signal Comparison Across All Four Compounds

| Compound | Primary Safety Data Source | Known/Reported Side Effects | Unresolved Concerns |

|---|---|---|---|

| Semax | Russian institutional trials | Nasal irritation (intranasal), generally mild | Limited Western surveillance; short half-life means narrow exposure windows |

| Selank | Russian institutional trials | Minimal reported; no dependency in short cycles | Immunomodulatory activity; incomplete mechanism characterization |

| Dihexa | Animal models only | Unknown in humans | MET agonism / theoretical oncogenic risk |

| Cerebrolysin | Multiple RCTs | Headache, GI effects in some trials; rare serious events in injection context | Quality and composition variability across batches |

The safety comparison here isn't straightforward. 'No reported side effects' in a small Russian institutional trial is not the same as 'safe for human use.' It means the trial population didn't report significant adverse effects in that context. Absence of evidence is not evidence of absence, particularly when trial populations are small and follow-up periods are short.

---

Legal and Regulatory Status by Region

United States

Semax, Selank, and Dihexa are not FDA-approved for any indication. They're not scheduled controlled substances under federal law as of the time of writing, which puts them in a legal grey area - not explicitly illegal to possess, but not legal to sell for human consumption. They're sold as 'research chemicals' under a regulatory framework that prohibits vendors from making human-use claims. The FDA has authority to take enforcement action against vendors who make therapeutic claims.

United Kingdom

None of the three are licensed medicines in the UK. They're not listed under the Misuse of Drugs Act as controlled substances. Importation for personal use occupies a grey area under MHRA jurisdiction. Selling them as medicines without a product licence is illegal.

European Union

Similar to the UK - not approved medicines, not generally scheduled as controlled substances, but sale as medicines without authorization is prohibited under EU pharmaceutical law. Regulatory enforcement varies by member state.

Australia

Australia's regulatory environment is comparatively strict. The TGA (Therapeutic Goods Administration) classifies unregistered peptides as prescription-only or prohibited imports depending on scheduling. Importation of unregistered therapeutic goods for personal use is subject to TGA Personal Importation Scheme conditions, with quantity limits. Semax and Selank are not TGA-registered. Dihexa has no approved status anywhere.

> Important: Regulatory status can change. Verify current status with relevant national authorities before making any sourcing decisions.

---

Sourcing Considerations: COA Standards, Vendor Red Flags, and Cold-Chain Requirements

What a Credible COA Should Include

A Certificate of Analysis from a legitimate third-party laboratory should specify:

• Peptide sequence confirmed (typically via HPLC or mass spectrometry)
• Purity percentage (research-grade peptides are typically 98%+ purity; anything below 95% warrants scrutiny)
• Water and TFA (trifluoroacetic acid) content - TFA is a common synthesis byproduct with independent biological activity and should be removed from high-quality research peptides
• Endotoxin testing (particularly relevant for injectable preparations)
• The testing laboratory should be identifiable and independent of the vendor

Vendor Red Flags

• COA produced by an in-house lab with no independent verification
• No mass spectrometry data confirming peptide identity (HPLC alone confirms purity, not identity)
• No cold-chain shipping for lyophilized peptides (though lyophilized powders are more stable than pre-mixed solutions)
• Vendors making human-use claims or therapeutic outcome promises - this signals regulatory non-compliance and correlates with lower quality standards
• No age verification or identity confirmation at purchase
• Pre-mixed aqueous Semax or Selank solutions shipped without cold packaging - both degrade rapidly in solution at room temperature

Cold-Chain Requirements

Lyophilized (freeze-dried) Semax and Selank are stable at room temperature during transport when sealed, but should be stored refrigerated long-term and frozen for periods exceeding a few months. Once reconstituted in solution, both degrade rapidly at room temperature - refrigerated solutions should typically be used within 2-4 weeks depending on formulation. Vendors selling pre-mixed intranasal solutions that aren't shipped cold and are marketed for extended ambient storage should be viewed with suspicion.

---

What the Evidence Does Not Yet Support: Claims to Treat With Appropriate Skepticism

The following claims appear regularly in community and vendor contexts. None are supported by adequate human trial evidence:

• That any of the three featured compounds treats, cures, or manages any neurological or psychiatric condition
• That Dihexa's rodent potency translates to cognitive improvement in humans
• That Semax or Selank are safe for long-term daily use (available trial data covers short-course protocols only)
• That intranasal delivery reliably achieves the CNS concentrations observed in animal model studies
• That anecdotal dose-response data from community forums constitutes meaningful safety or efficacy evidence
• That the absence of reported serious adverse effects in small trials establishes a clean long-term safety profile

The field is genuinely interesting. The mechanisms are biologically plausible. Some of the institutional data is more substantial than most people in Western research communities realize. None of this changes the current evidence tier for any of these compounds.

---

Regulatory Disclaimer and Research Context Statement

All compounds covered in this guide are sold as research chemicals in Western jurisdictions and are not approved for human consumption by the FDA, MHRA, TGA, or EMA. This content is published for educational purposes only and does not constitute medical advice. Nothing in this guide should be interpreted as a recommendation to obtain, administer, or experiment with any of the compounds described. Readers with health concerns should consult a qualified medical professional. Regulatory status varies by jurisdiction and is subject to change.